Bausch Health Companies Inc. (NYSE:BHC) Receives Average Recommendation of “Reduce” from Analysts

Shares of Bausch Health Companies Inc. (NYSE:BHC) have been assigned a consensus recommendation of “Reduce” from the seven brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $7.42.

Several equities analysts have recently weighed in on BHC shares. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. Royal Bank of Canada reduced their price target on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research report on Thursday, January 30th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $8.00 price objective (down previously from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th.

Institutional Investors Weigh In On Bausch Health Companies

Several hedge funds have recently added to or reduced their stakes in the company. Maple Rock Capital Partners Inc. lifted its stake in Bausch Health Companies by 156.7% during the fourth quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company’s stock worth $42,718,000 after purchasing an additional 3,235,100 shares during the last quarter. One68 Global Capital LLC bought a new stake in Bausch Health Companies during the fourth quarter worth about $90,000. The Manufacturers Life Insurance Company lifted its stake in Bausch Health Companies by 5.7% during the fourth quarter. The Manufacturers Life Insurance Company now owns 260,378 shares of the company’s stock worth $2,108,000 after purchasing an additional 14,042 shares during the last quarter. Aquatic Capital Management LLC bought a new stake in Bausch Health Companies during the fourth quarter worth about $202,000. Finally, Credit Industriel ET Commercial bought a new stake in Bausch Health Companies during the fourth quarter worth about $377,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Performance

Shares of NYSE BHC opened at $6.15 on Monday. The stock has a market cap of $2.22 billion, a PE ratio of -12.82, a price-to-earnings-growth ratio of 0.34 and a beta of 0.68. Bausch Health Companies has a fifty-two week low of $3.96 and a fifty-two week high of $11.46. The stock has a fifty day moving average of $7.48 and a 200-day moving average of $7.47.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.